REFERENCES
- Glimelius B., Hoffmann K., Sjoeden P.-O., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 1996; 7: 593–600
- Burris H. A., III, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15: 2403–2413
- Berlin J. D., Catalano P., Thomas J. P., Kugler J. W., Haller D. G., Benson A. B., III. Phase III, study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002; 20: 3270–3275
- Moore M. J., Hamm J., Dancey J., Eisenberg P. D., Dagenais M., Fields A., et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2003; 21: 3296–3302
- Rocha Lima C. M.S., Green M. R., Rotche R., Miller W. H., Jr., Jeffrey G. M., Cisar L. A., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 2004; 22: 3776–3783
- Bramhall S. R., Schultz J., Nemunaitis J., Brown P. D., Baillet M., Buckels J. A.C. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 2002; 87: 161–167
- Bramhall S. R., Rosemurgy A., Brown P. D., Bowry C., Buckels J. A., for the Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 2001; 19: 3477–3455
- Heinemann V., Quietzsch D., Gieseler F., Gonnermann N., Schonekas H., Rost A., et al. Randomized Phase III, trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 2006; 24: 3946–3952
- Van Cutsem E., van de Velde H., Karasek P., Oettle H., Vervenne W. L., Szawlowski A., et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004; 22: 1430–1438
- Reni M., Cordio S., Milandri C., et al. Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a Phase III trial. Lancet Oncol. 2005; 6: 369–376
- Moore M. J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007; 25, published ahead of print on April 23, 2007
- Reni M., Passoni P., Panucci M. G., et al. Definitive results of a Phase II trial of PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine) in Stage IV pancreatic adenocarcinoma. J. Clin. Oncol. 2001; 19: 2679–2686
- Reni M., Bonetto E., Cordio S., et al. Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a Phase III randomized trial. Pancreatology 2006; 6: 454–463
- International Union Against Cancer. TNM classification of malignant tumours, 5th ed., L. H. Sobin, C. Wittekind. Wiley-Liss, New York 1997
- Reni M., Passoni P., Bonetto E., et al. Final results of a prospective trial of a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology 2005; 68: 239–245
- Ajani J. A., Welch S. R., Raber M. N., Fields W. S., Krakoff I. H. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990; 8: 147–159